GenSci048

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

EndometriosisUveitisConnective Tissue Disease

60 competitors in Endometriosis

#DrugCompanyPhaseTrials

1

Danocrine

Sanofi

Approved

52

Bayer Aspirin

Bayer

Approved

23

Orilissa

AbbVie

Phase 3

164

Estrace

Novo Nordisk

Approved

—5

IC-Green

PProvepharm SAS

Approved

46

Ketalar

AAultman Health Foundation

Approved

27

Catapres

Boehringer Ingelheim

Approved

18

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

19

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Approved

110

Trelstar

OOncoVerity, Inc.

Approved

1Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Connective Tissue Disease1 trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06189495·30 enrolled

Endometriosis1 trial

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06963177·200 enrolled

Uveitis1 trial

A Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.

Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT07547995·74 enrolled

Details

Drug Info

Related News